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Abstract: Phyllodes tumors (PTs) are classified as fibroepithelial tumors and their histologic grade is determined 
primarily by the features of the stromal component. In this study, we examined the expression profiles of autophagy-
related proteins in the stromal component of PTs and analyzed their clinical implications. We selected 204 human 
PT samples which were excised and diagnosed at Severance Hospital from 2000 to 2008 and created tissue micro-
array (TMA) blocks. Immunohistochemical assays for autophagy-related proteins (beclin-1, LC3A, LC3B, and p62) 
were then performed on these samples. The surgical specimens from higher grade PTs less frequently displayed 
cytoplasmic expression of beclin-1, LC3A, LC3B, and p62 in the stromal component (p<0.001). In univariate analy-
sis, the following profiles were associated with shorter disease-free survival and overall survival: nuclear beclin-1 
positivity in the stromal component (p=0.013 and p=0.044, respectively), LC3A positivity in the stromal component 
(p<0.001 and p<0.001, respectively), and p62 positivity in the stromal component (p=0.012 and p=0.004, respec-
tively). In conclusion, we determined that increased activity of autophagy-related proteins correlated with a higher 
histologic grade and poorer prognosis in PTs. These results lead us to conclude that the autophagy activity of the 
stromal cells plays a key role in the progression of PTs.
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Introduction
Phyllodes tumor (PT) is a relatively uncommon 
fibroepithelial tumor, comprising only 0.3-1.5% 
of all breast tumors [1]. However, it is hard to 
distinguish PT from other fibroepithelial tumors 
because of its heterogeneous histologic fea-
tures [1, 2]. Although PT contains both epithe-
lial and stromal components which could be 
neoplastic, on histological grading, it is classi-
fied primarily by the features of the stromal 
components as follows: cytologic atypia of stro-
mal cells, stromal hypercellularity and over-
growth, sarcomatous change, and mitotic activ-
ity [3, 4]. Clinically, high-grade PTs can present 
with malignant behaviors such as local recur-
rence or distant metastasis. Therefore, it is 
necessary to discover reliable markers for the 
malignant features of the stromal component 
to accurately predict tumor progression. 
Autophagy is defined as a catabolic pathway of 
lysosomal degradation of the cellular compo-
nents. Among the three types of autophagy, 
macroautophagy particularly involves the 
stress-response pathway to maintain cellular 
homeostasis by removal of dysfunctional or 
damaged cellular components, as well as by 
recycling useful cellular components [5-9]. In 
this study, autophagy is referred to as macroau-
tophagy to explain the cellular process within 
the cancer cells. 
Cancer cells thrive in harsh environments, such 
as hypoxic or low nutrient states, surviving 
through angiogenesis and/or aerobic glycolysis. 
However, in the case of aggressive malignant 
tumors, it is hard for cancer cells to meet the 
high metabolic demand so that they cannot 
fully recover using the classical pathways. 
Autophagy as an alternative metabolic pathway 
conserves energy within the cancer cells by 
recycling cytoplasmic components [10, 11]. In 
contrast, unrestrained autophagy could induce 
progressive consumption of cellular constitu-
ents and ultimately lead to cell death [12, 13]. 
Interestingly, autophagy has a profound effect 
on both tumor suppression and tumor progres-
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sion. However, not much was known about the 
expression profiles of autophagy-related pro-
teins in PTs until recently. 
In this study, we explored the relevance of 
autophagy-related protein expression patterns 
and histologic grade in human PTs. On the 
basis of this observation, we evaluated the abil-
ity of autophagy-related proteins to predict 
prognosis. 
Methods and materials
Patient selection and clinicopathologic analy-
sis
This retrospective study was approved by the 
institutional review board of Yonsei University 
Severance Hospital. Our inclusion criteria 
defined a study population of 204 patients who 
had been histologically diagnosed with PT after 
having tumors excised at Yonsei University 
Severance Hospital from 2000 to 2008. All tis-
sues were fixed in 10% buffered formalin and 
embedded in paraffin. All archival hematoxylin 
and eosin (H&E)–stained slides were reviewed 
by three pathologists and histologic grading 
was performed based on the criteria of the 
WHO Blue Book [1]. Histologic parameters such 
as stromal cellularity (mild, moderate, and 
severe), stromal atypia (mild, moderate, and 
severe), stromal mitosis (10 HPFs), stromal 
overgrowth, and tumor margin (expanding or 
infiltrative) were evaluated on H&E–stained 
slides. Included clinical parameters were 
patient age at initial diagnosis, sex, tumor 
recurrence, and tumor metastasis. 
Tissue microarray
We selected formalin-fixed paraffin-embedded 
(FFPE) tumor tissue samples after retrospec-
tive review of H&E–stained slides of human 
PTs. The most representative areas of each 
tumor sample were assembled in a 5x4 array 
after extraction of tumor cores as small as 5 
mm in diameter. We attempted to include all of 
the epithelial and stromal components of PTs in 
the recipient blocks. Each PT sample had two 
tissue cores in TMA and each separate tissue 
core was assigned a unique tissue microarray 
location number that was linked to a database 
including other clinicopathologic data.
Immunohistochemistry
All immunostainings were performed using 
FFPE tissue sections. Five μm-thick sections 
were obtained with a microtome, transferred 
onto adhesive slides, and dried at 62°C for 30 
minutes. After incubation with primary antibod-
ies for beclin-1 (polyclonal, 1:100, Abcam, 
Cambridge, UK), LC3A (EP1528Y, 1:100, 
Abcam, Cambridge, UK), LC3B (polyclonal, 
1:100, Abcam, Cambridge, UK), and p62 
(SQSTM1, 1:100, Abcam, Cambridge, UK), 
immunodetection was performed with biotinyl-
ated anti-mouse immunoglobulin, followed by 
peroxidase-labeled streptavidin using a labeled 
streptavidin biotin kit with 3,3′-diaminobenzi-
dine chromogen as substrate. Optimal primary 
antibody incubation time and concentration 
were determined via serial dilution for each 
immunohistochemical assay with an identically 
fixed and embedded tissue block. The primary 
antibody incubation step was omitted in the 
negative control. A positive control was includ-
ed for each experiment; Beclin-1: normal breast 
tissue, LC3A and LC3B: brain tissue, and p62: 
spleen tissue. Slides were counterstained with 
Harris hematoxylin. The staining was interpret-
ed by two pathologists on a multiview 
microscope. 
For measurement of immunostaining intensity, 
we divided PTs in four groups as follows: 0 (neg-
ative), 1 (weakly positive), 2 (moderately posi-
tive), and 3 (strongly positive). For measure-
ment of proportion of stained cells, we divided 
PTs in three groups as follows: 1 (negative), 2 
(positive less than 30%), and 3 (positive more 
than 30%). Our indication standard for estima-
tion of immunohistochemical results for beclin- 
1, LC3A, LC3B, and p62 was immunostaining 
intensity multiplied by the proportion of stained 
cells. The total score after multiplication was 
divided as follows: 0 to 1 as negative and 2 to 9 
as positive [14].
Statistical analysis 
Data were processed using SPSS for Windows, 
version 12.0 (SPSS Inc., Chicago, IL, USA). 
Student’s t and Fisher’s exact tests were used 
to examine any difference in continuous and 
categorical variables, respectively. When ana-
lyzing data with multiple comparisons, a 
corrected p-value with application of Bonferroni 
multiple comparison procedure was used. 
Significance was assumed when P<0.05. Ka- 
plan-Meier survival curves and log-rank statis-
tics were employed to evaluate time to tumor 
metastasis and time to survival. Multivariate 
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regression analysis was performed using the 
Cox proportional hazards model.
Results
Expression of autophagy-related proteins ac-
cording to the histologic grade of PT
In Table 1, we compared the histologic grade of 
204 PTs to the other parameters, and found 
that a higher histologic grade was associated 
with increased stromal cellularity, atypia, mito-
sis, overgrowth, infiltrative tumor margin, and 
frequent tumor recurrence and metastasis 
(p<0.001). To examine autophagy activity in the 
PTs, we performed immunohistochemistry of 
autophagy-related proteins (Figure 1). Proteins 
used to assess autophagy activities were as 
follows: beclin-1 as a participant in nucleation 
[15-18], LC3 as a participant in autophago-
some formation [19-21], and p62 as a scaffold 
protein that conveys ubiquitinated proteins to 
the autophagosome [22, 23]. Figure 2 is a rep-
resentative heatmap of the expression of 
autophagy-related proteins according to the 
histologic grade of PTs. On immunohistochemi-
cal analysis, a higher histologic grade correlat-
ed with increased expression of autophagy-
related proteins in the stromal component 
(p<0.001), although the epithelial component 
had nothing distinctive about it (Tables 2-4). 
We assumed that the autophagy activity in the 
stromal component had a major impact on 
tumor progression in PTs. 
When looking at the effect of autophagy activity 
on the progression of PT, we examined the cor-
relation between expressions of autophagy-
related proteins with clinicopathologic parame-
ters (Tables 2-4). As a result, expression of 
beclin-1, LC3A, LC3B, and p62 in the stromal 
cells, but not in the epithelial cells, was associ-
ated with increased stromal cellularity, increa- 
sed stromal atypia, increased stromal mitosis, 
and stromal overgrowth (p<0.05). Particularly, 
LC3A expression of the stromal component 
Table 1. Clinicopathologic characteristics of patients with phyllodes tumor
Parameter Number of Patients 
N=204 (%)
Phyllodes tumor (%)
P-valueBenign  
N=156
Borderline  
N=32
Malignant  
N=16
Age (years, mean±SD) 40.2±12.3 38.9±12.2 43.1±11.0 47.6±12.9 0.009
Tumor size (Cm, mean±SD) 4.0±2.6 3.6±2.1 4.2±2.5 6.7±4.6 <0.001
Stromal cellularity <0.001
Mild 123 (60.3) 122 (78.2) 1 (3.1) 0 (0.0)
Moderate 68 (33.3) 34 (21.8) 27 (84.4) 7 (43.8)
Marked 13 (6.4) 0 (0.0) 4 (12.5) 9 (56.3)
Stromal atypia <0.001
Mild 161 (78.9) 154 (98.7) 7 (21.9) 0 (0.0)
Moderate 33 (16.2) 2 (1.3) 23 (71.9) 8 (50.0)
Marked 10 (4.9) 0 (0.0) 2 (6.3) 8 (50.0)
Stromal mitosis <0.001
0–4 / 10 HPFs 159 (77.9) 156 (100.0) 3 (9.4) 0 (0.0)
5–9 / 10 HPFs 34 (16.7) 0 (0.0) 29 (90.6) 5 (31.3)
≥10 / 10 HPFs 11 (5.4) 0 (0.0) 0 (0.0) 11 (68.8)
Stromal overgrowth <0.001
Absent 187 (91.7) 156 (100.0) 29 (90.6) 2 (12.5)
Present 17 (8.3) 0 (0.0) 3 (9.4) 14 (87.5)
Tumor margin <0.001
Circumscribed 183 (89.7) 153 (98.1) 24 (75.0) 6 (37.5)
Infiltrative 21 (10.3) 3 (1.9) 8 (25.0) 10 (62.5)
Tumor local recurrence 18 (8.8) 5 (3.2) 6 (18.8) 7 (43.8) <0.001
Distance metastasis 8 (3.9) 0 (0.0) 1 (3.1) 7 (43.8) <0.001
SD, standard deviation; HPFs, high-power fields.
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was significantly associated with tumor recur-
rence and distant metastasis (p=0.010, and 
<0.001, respectively).
Impact of autophagy-related proteins on pa-
tient prognosis
Based on the above observation, we investi-
gated the effect of each autophagy-related pro-
tein on the prognosis of the PT patients (Figure 
3). We performed univariate analysis (Table 5) 
and found that factors associated with shorter 
disease-free survival and shorter overall sur-
vival were nuclear beclin-1 positivity in the stro-
mal component (p=0.013, and p=0.044, res- 
pectively), LC3A positivity in the stromal com-
ponent (p<0.001, and p<0.001, respectively), 
and p62 positivity in the stromal component 
Figure 1. Immunohistochemical stains of autophagy-related proteins in phyllodes tumors. Expression of cytoplas-
mic beclin-1, LC3A, LC3B, and p62 in the stromal component increases as the histologic grade of phyllodes tumor 
increases.
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(p=0.012, and p=0.004, respectively). Next, we 
performed Cox multivariate analysis (parame-
ters included were stromal cellularity, stromal 
atypia, stromal mitosis, stromal overgrowth, 
Figure 2. A heatmap of the expression of autophagy-related proteins according to the histologic grade of phyllodes 
tumor. 
Table 2. Expression of autophagy-related proteins according to the histologic grade of phyllodes 
tumor
Parameter Number of Patients
N=204 (%)
Phyllodes tumor (%)
P-valueBenign
N=156 
Borderline
N=32 
Malignant
N=16 
Nuclear beclin-1 (E)* 0.232
    Negative 111 (58.4) 95 (60.9) 13 (44.8) 3 (60.0)
    Positive 79 (41.6) 61 (39.1) 16 (55.2) 2 (40.0)
Cytoplasmic beclin-1 (E)* 0.933
    Negative 101 (53.2) 84 (53.8) 13 (44.8) 4 (80.0)
    Positive 89 (46.8) 72 (46.2) 16 (55.2) 1 (20.0)
Nuclear beclin-1 (S) 0.090
    Negative 188 (92.2) 149 (95.5) 23 (71.9) 16 (100.0)
    Positive 16 (7.8) 7 (4.5) 9 (28.1) 0 (0.0)
Cytoplasmic beclin-1 (S) <0.001
    Negative 183 (89.7) 147 (94.2) 26 (81.3) 10 (62.5)
    Positive 21 (10.3) 9 (5.8) 6 (18.8) 6 (37.5)
LC3A (E)* 0.980
    Negative 185 (97.4) 152 (97.4) 28 (96.6) 5 (100.0)
    Positive 5 (2.6) 4 (2.6) 1 (3.4) 0 (0.0)
LC3A (S) <0.001
    Negative 148 (72.5) 127 (81.4) 19 (59.4) 2 (12.5)
    Positive 56 (27.5) 29 (18.6) 13 (40.6) 14 (87.5)
LC3B (E)* 0.421
    Negative 34 (17.9) 30 (19.2) 3 (10.3) 1 (20.0)
    Positive 156 (82.1) 126 (80.8) 26 (89.7) 4 (80.0)
LC3B (S) <0.001
    Negative 145 (71.1) 126 (80.8) 14 (43.8) 5 (31.3)
    Positive 59 (28.9) 30 (19.2) 18 (56.3) 11 (68.8)
p62 (E)* 0.650
    Negative 161 (84.7) 134 (85.9) 22 (75.9) 5 (100.0)
    Positive 29 (15.3) 22 (14.1) 7 (24.1) 0 (0.0)
p62 (S) <0.001
    Negative 140 (68.6) 122 (78.2) 14 (43.8) 4 (25.0)
    Positive 64 (31.4) 34 (21.8) 18 (56.3) 12 (75.0)
*14 cases without an epithelial component were excluded. E, epithelial component. S, stromal component.
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Table 3. Correlation between clinicopathologic factors with expression of autophagy-related proteins in epithelial component*
Parameters
Nuclear beclin-1 Cytoplasmic beclin-1 LC3A LC3B P62
(-) n=111 
(%)
(+) n=79 
(%)
p-
value
(-) n=101 
(%)
(+) n=89 
(%)
p-
value
(-) n=185 
(%)
(+) n=5 
(%)
p-
value
(-) n=34 
(%)
(+) n=156 
(%)
p-
value
(-) n=161 
(%)
(+) n=29 
(%)
p-
value
Stromal cellularity 1.065 4.155 1.865 2.385 1.470
    Mild 78 (70.3) 45 (57.0) 66 (65.3) 57 (64.0) 121 (65.4) 2 (40.0) 25 (73.5) 98 (62.8) 107 (66.5) 16 (55.2)
    Moderate 28 (25.2) 33 (41.8) 32 (31.7) 29 (32.6) 58 (31.4) 3 (60.0) 7 (20.6) 54 (34.8) 49 (30.4) 12 (41.4)
    Marked 5 (4.5) 1 (1.3) 3 (3.0) 3 (3.4) 6 (3.2) 0 (0.0) 2 (5.9) 4 (2.6) 5 (3.1) 1 (3.4)
Stromal atypia 0.220 3.620 4.315 2.160 0.230
    Mild 99 (89.2) 62 (78.5) 87 (86.1) 74 (83.1) 157 (84.9) 4 (80.0) 31 (91.2) 130 (83.3) 140 (87.0) 21 (72.4)
    Moderate 11 (9.9) 15 (19.0) 12 (11.9) 14 (15.7) 25 (13.5) 1 (20.0) 2 (5.9) 24 (15.4) 19 (11.8) 7 (24.1)
    Marked 1 (0.9) 2 (2.5) 2 (2.0) 1 (1.1) 3 (1.6) 0 (0.0) 1 (2.9) 2 (1.3) 2 (1.2) 1 (3.4)
Stromal mitosis 1.175 2.905 4.415 3.370 3.165
    0–4 / 10 HPFs 96 (86.5) 63 (79.7) 86 (85.1) 73 (82.0) 155 (83.8) 4 (80.0) 30 (88.2) 129 (82.7) 136 (84.5) 23 (79.3)
    5–9 / 10 HPFs 14 (12.6) 15 (19.0) 14 (13.9) 15 (16.9) 28 (15.1) 1 (20.0) 3 (8.8) 26 (16.7) 23 (14.3) 6 (20.7)
    ≥10 / 10 HPFs 1 (0.9) 1 (1.3) 1 (1.0) 1 (1.1) 2 (1.1) 0 (0.0) 1 (2.9) 1 (0.6) 2 (1.2) 0 (0.0)
Stromal overgrowth 2.855 5.000 5.000 2.240 5.000
    Absent 110 (99.1) 77 (97.5) 99 (98.0) 88 (98.9) 182 (98.4) 5 (100.0) 33 (97.1) 154 (98.7) 158 (98.1) 29 (100.0)
    Present 1 (0.9) 2 (2.5) 2 (2.0) 1 (1.1) 3 (1.6) 0 (0.0) 1 (2.9) 2 (1.3) 3 (1.9) 0 (0.0)
Tumor margin 5.000 3.945 0.220 5.000 3.495
    Circumscribed 103 (92.8) 73 (92.4) 93 (92.1) 83 (93.3) 173 (93.5) 3 (60.0) 32 (94.1) 144 (92.3) 148 (91.9) 28 (96.6)
    Infiltrative 8 (7.2) 6 (7.6) 8 (7.9) 6 (6.7) 12 (6.5) 2 (40.0) 2 (5.9) 12 (7.7) 13 (8.1) 1 (3.4)
Tumor recurrence 9 (8.1) 3 (3.8) 1.825 5 (5.0) 7 (7.9) 2.765 12 (6.5) 0 (0.0) 5.000 3 (8.8) 9 (5.8) 2.265 12 (7.5) 0 (0.0) 1.095
Distance metastasis 2 (1.8) 0 (0.0) 2.560 1 (1.0) 1 (1.1) 5.000 2 (1.1) 0 (0.0) 5.000 0 (0.0) 2 (1.3) 5.000 2 (1.2) 0 (0.0) 5.000
*14 cases without an epithelial component were excluded.
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Table 3. Correlation between clinicopathologic factors with expression of autophagy-related proteins in epithelial component*
Parameters
Nuclear beclin-1 Cytoplasmic beclin-1 LC3A LC3B P62
(-) n=111 
(%)
(+) n=79 
(%)
p-
value
(-) n=101 
(%)
(+) n=89 
(%)
p-
value
(-) n=185 
(%)
(+) n=5 
(%)
p-
value
(-) n=34 
(%)
(+) n=156 
(%)
p-
value
(-) n=161 
(%)
(+) n=29 
(%)
p-
value
Stromal cellularity 1.065 4.155 1.865 2.385 1.470
    Mild 78 (70.3) 45 (57.0) 66 (65.3) 57 (64.0) 121 (65.4) 2 (40.0) 25 (73.5) 98 (62.8) 107 (66.5) 16 (55.2)
    Moderate 28 (25.2) 33 (41.8) 32 (31.7) 29 (32.6) 58 (31.4) 3 (60.0) 7 (20.6) 54 (34.8) 49 (30.4) 12 (41.4)
    Marked 5 (4.5) 1 (1.3) 3 (3.0) 3 (3.4) 6 (3.2) 0 (0.0) 2 (5.9) 4 (2.6) 5 (3.1) 1 (3.4)
Stromal atypia 0.220 3.620 4.315 2.160 0.230
    Mild 99 (89.2) 62 (78.5) 87 (86.1) 74 (83.1) 157 (84.9) 4 (80.0) 31 (91.2) 130 (83.3) 140 (87.0) 21 (72.4)
    Moderate 11 (9.9) 15 (19.0) 12 (11.9) 14 (15.7) 25 (13.5) 1 (20.0) 2 (5.9) 24 (15.4) 19 (11.8) 7 (24.1)
    Marked 1 (0.9) 2 (2.5) 2 (2.0) 1 (1.1) 3 (1.6) 0 (0.0) 1 (2.9) 2 (1.3) 2 (1.2) 1 (3.4)
Stromal mitosis 1.175 2.905 4.415 3.370 3.165
    0–4 / 10 HPFs 96 (86.5) 63 (79.7) 86 (85.1) 73 (82.0) 155 (83.8) 4 (80.0) 30 (88.2) 129 (82.7) 136 (84.5) 23 (79.3)
    5–9 / 10 HPFs 14 (12.6) 15 (19.0) 14 (13.9) 15 (16.9) 28 (15.1) 1 (20.0) 3 (8.8) 26 (16.7) 23 (14.3) 6 (20.7)
    ≥10 / 10 HPFs 1 (0.9) 1 (1.3) 1 (1.0) 1 (1.1) 2 (1.1) 0 (0.0) 1 (2.9) 1 (0.6) 2 (1.2) 0 (0.0)
Stromal overgrowth 2.855 5.000 5.000 2.240 5.000
    Absent 110 (99.1) 77 (97.5) 99 (98.0) 88 (98.9) 182 (98.4) 5 (100.0) 33 (97.1) 154 (98.7) 158 (98.1) 29 (100.0)
    Present 1 (0.9) 2 (2.5) 2 (2.0) 1 (1.1) 3 (1.6) 0 (0.0) 1 (2.9) 2 (1.3) 3 (1.9) 0 (0.0)
Tumor margin 5.000 3.945 0.220 5.000 3.495
    Circumscribed 103 (92.8) 73 (92.4) 93 (92.1) 83 (93.3) 173 (93.5) 3 (60.0) 32 (94.1) 144 (92.3) 148 (91.9) 28 (96.6)
    Infiltrative 8 (7.2) 6 (7.6) 8 (7.9) 6 (6.7) 12 (6.5) 2 (40.0) 2 (5.9) 12 (7.7) 13 (8.1) 1 (3.4)
Tumor recurrence 9 (8.1) 3 (3.8) 1.825 5 (5.0) 7 (7.9) 2.765 12 (6.5) 0 (0.0) 5.000 3 (8.8) 9 (5.8) 2.265 12 (7.5) 0 (0.0) 1.095
Distance metastasis 2 (1.8) 0 (0.0) 2.560 1 (1.0) 1 (1.1) 5.000 2 (1.1) 0 (0.0) 5.000 0 (0.0) 2 (1.3) 5.000 2 (1.2) 0 (0.0) 5.000
*14 cases without an epithelial component were excluded.
Table 4. Correlation between clinicopathologic factors with expression of autophagy-related proteins in stromal component
Parameters
Nuclear beclin-1 Cytoplasmic beclin-1 LC3A LC3B P62
(-) n=188 
(%)
(+) n=16 
(%)
p-val-
ue*
(-) n=183 
(%)
(+) n=21 
(%)
p-val- 
ue*
(-) n=148 
(%)
(+) n=56 
(%)
p-val- 
ue*
(-) n=145 
(%)
(+) n=59 
(%)
p-val- 
ue*
(-) n=140 
(%)
(+) n=64 
(%)
p-val- 
ue*
Stromal cellularity 0.250 0.010 <0.001 <0.001 <0.001
    Mild 118 (62.8) 5 (31.3) 116 (63.4) 7 (33.3) 107 (72.3) 16 (28.6) 103 (71.0) 20 (33.9) 100 (71.4) 23 (35.9)
    Moderate 58 (30.9) 10 (62.5) 58 (31.7) 10 (47.6) 37 (25.0) 31 (55.4) 40 (27.6) 28 (47.5) 34 (24.3) 34 (53.1)
    Marked 12 (6.4) 1 (6.3) 9 (4.9) 4 (19.0) 4 (2.7) 9 (16.1) 2 (1.4) 11 (18.6) 6 (4.3) 7 (10.9)
Stromal atypia 0.850 <0.001 <0.001 <0.001 <0.001
    Mild 152 (80.9) 9 (56.3) 152 (83.1) 9 (42.9) 131 (88.5) 30 (53.6) 128 (88.3) 33 (55.9) 126 (90.0) 35 (54.7)
    Moderate 26 (13.8) 7 (43.8) 25 (13.7) 8 (38.1) 15 (10.1) 18 (32.1) 13 (9.0) 20 (33.9) 13 (9.3) 20 (31.3)
    Marked 10 (5.3) 0 (0.0) 6 (3.3) 4 (19.0) 2 (1.4) 8 (14.3) 4 (2.8) 6 (10.2) 1 (0.7) 9 (14.1)
Stromal mitosis 0.155 <0.001 <0.001 <0.001 <0.001
    0–4 / 10 HPFs 152 (80.9) 7 (43.8) 150 (82.0) 9 (42.9) 130 (87.8) 29 (51.8) 129 (89.0) 30 (50.8) 124 (88.6) 35 (54.7)
    5–9 / 10 HPFs 25 (13.3) 9 (56.3) 25 (13.7) 9 (42.9) 16 (10.8) 18 (32.1) 13 (9.0) 21 (35.6) 13 (9.3) 21 (32.8)
    ≥10 / 10 HPFs 11 (5.9) 0 (0.0) 8 (4.4) 3 (14.3) 2 (1.4) 9 (16.1) 3 (2.1) 8 (13.6) 3 (2.1) 8 (12.5)
Stromal overgrowth 3.145 0.015 <0.001 <0.001 <0.001
    Absent 173 (92.0) 14 (87.5) 172 (94.0) 15 (71.4) 145 (98.0) 42 (75.0) 142 (97.9) 45 (76.3) 136 (97.1) 51 (79.7)
    Present 15 (8.0) 2 (12.5) 11 (6.0) 6 (28.6) 3 (2.0) 14 (25.0) 3 (2.1) 14 (23.7) 4 (2.9) 13 (20.3)
Tumor margin 3.365 1.215 <0.001 0.005 0.060
    Circumscribed 169 (89.9) 14 (87.5) 166 (90.7) 17 (81.0) 141 (95.3) 42 (75.0) 137 (94.5) 46 (78.0) 131 (93.6) 52 (81.3)
    Infiltrative 19 (10.1) 2 (12.5) 17 (9.3) 4 (19.0) 7 (4.7) 14 (25.0) 8 (5.5) 13 (22.0) 9 (6.4) 12 (18.8)
Tumor recurrence 14 (7.4) 4 (25.0) 0.200 16 (8.7) 2 (9.5) 5.000 7 (4.7) 11 (19.6) 0.010 10 (6.9) 8 (13.6) 0.855 8 (5.7) 10 (15.6) 0.155
Distance metastasis 7 (3.7) 1 (6.3) 2.440 6 (3.3) 2 (9.5) 0.970 0 (0.0) 8 (14.3) <0.001 4 (2.8) 4 (6.8) 1.160 2 (1.4) 6 (9.4) 0.065
*p-values are corrected for multiple testing using the Bonferroni correction. 
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organs [15, 18, 20, 24-31]. In terms of breast 
tumors, it is also known that expression of 
autophagy-related markers are associated with 
the histologic grade and the molecular subtype 
of breast cancer, although there is still no valid 
research evaluating the autophagy status in 
PTs [25].
Autophagy induction in cancer cells can occur 
due to hypoxia [10], and it has been previously 
demonstrated that expression of hypoxia-
inducible factor 1 alpha (HIF-1α) and its down-
stream targets are associated with a higher 
histologic grade in fibroepithelial tumors of the 
breast [32]. Higher-grade PTs have been found 
to have relatively more stromal overgrowth than 
the lower-grade PTs, which is attributed to the 
fact that they frequently experience more 
hypoxia in the tumor microenvironment. It is 
thought that autophagy provides the nutrients 
needed for cancer survival and expression of 
HIF-1α allows higher-grade PTs to adapt to 
hypoxia. Furthermore, the metabolic demand 
has been shown to be elevated in higher-grade 
PTs based on the report that the expression of 
glycolysis-related proteins is associated with 
the histologic grade of PTs [33]. Therefore, we 
suggested that autophagy activity could com-
pensate for the metabolic demand required for 
tumor survival up to a point. However, the acti-
vation of autophagy has a flip-side: tumor sup-
tumor margin, nuclear beclin-1 in the stromal 
component, LC3A in the stromal component, 
and p62 in the stromal component); the results 
are shown in Table 6. Stromal overgrowth (haz-
ard ratio: 12.381, 95% CI: 1.991-76.978, 
P=0.007), and nuclear beclin-1 positivity in the 
stromal component (hazard ratio: 3.358, 95% 
CI: 1.023-12.371, P=0.046) were correlated 
with shorter disease-free survival and stromal 
overgrowth (hazard ratio: 111.262, 95% CI: 
6.175-2004.642, P=0.007) was associated 
with shorter overall survival. 
Finally, we found that the expression of autoph-
agy-related proteins adversely affected the 
disease-free survival and the overall survival of 
patients with PTs. 
Discussion
It is known that autophagy is involved in both 
tumor suppression and tumor progression [10-
13]. In this study, we investigated the expres-
sion profiles of autophagy-related proteins, 
beclin-1, LC3A, LC3B, and p62, in human PTs. 
We found that a higher histologic grade of PT 
was correlated with greater expression of 
beclin-1, LC3A, LC3B, and p62 proteins in the 
stromal component (p<0.001). These results 
support those of previous studies which have 
been performed in tumors from several other 
Figure 3. Disease-free survival and overall survival curves according to the status of autophagy-related proteins.
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study on the correlation of the expression and 
the localization of beclin-1 and prognosis of 
tumors is performed. Otherwise, the expres-
sion of LC3B and p62 is known to be associat-
ed with poor prognosis in tumors of other 
organs, consistent with our results [38, 39].
We performed immunohistochemical analysis, 
a static method, for evaluation of autophagy 
activity. However, autophagy is a multi-step 
dynamic process and thus, autophagy flux 
should be measured to evaluate the variations 
of autophagy activity over time [23]. Accordingly, 
pression may occur in the form of cell death 
induced by excessive consumption of the cel-
lular components [12, 13]. 
In terms of our results, the expression of nucle-
ar beclin-1, LC3B, and p62 in the stromal com-
ponent was related to poor prognosis in PT 
patients. Particularly, nuclear expression of 
beclin-1 in the stromal component was associ-
ated with shorter disease-free survival in multi-
variate analysis. We ascertained that beclin-1 
could be expressed both in the nucleus and the 
cytoplasm as seen in the results of preceding 
Table 5. Univariate analysis of the impact of expression of autophagy-relat-
ed proteins on prognosis by the log-rank test
Parameter
Disease-free survival Overall survival
Median survival 
(95% CI) months
P-value Median survival 
(95% CI) months
P-value
Nuclear beclin-1 (E)* 0.247 0.750
    Negative 168 (159-177) 181 (177-184)
    Positive 171 (164-179) 176 (172-181)
Cytoplasmic beclin-1 (E)* 0.319 n/a
    Negative 174 (167-181) n/a
    Positive 161 (150-172) n/a
Nuclear beclin-1 (S) 0.013 0.044
    Negative 169 (162-176) 177 (172-181)
    Positive 74 (56-91) 84 (69-98)
Cytoplasmic beclin-1 (S) 0.748 0.107
    Negative 167 (160-174) 177 (172-181)
    Positive 86 (75-97) 86 (76-97)
LC3A (E)* n/a n/a
    Negative n/a n/a
    Positive n/a n/a
LC3A (S) <0.001 <0.001
    Negative 174 (168-180) 181 (179-184)
    Positive 121 (106-136) 130 (116-144)
LC3B (E)* 0.515 0.173
    Negative 146 (132-160) 154 (146-163)
    Positive 172 (165-179) 181 (179-184)
LC3B (S) 0.119 <0.001
    Negative 170 (162-177) 181 (178-184)
    Positive 155 (140-170) 158 (144-172)
p62 (E)* n/a n/a
    Negative n/a n/a
    Positive n/a n/a
p62 (S) 0.012 0.004
    Negative 172 (165-179) 180 (176-183)
    Positive 120 (107-132) 129 (120-139)
*14 cases without an epithelial component were excluded. E, epithelial component. S, stromal 
component.
studies [25, 34]. In a 
study on brain tum- 
ors, beclin-1 protein 
shuttled between the 
nucleus and the cyto-
plasm and this expr- 
ession shift was 
explained by loss of 
beclin-1 gene func-
tion [34]. In addition, 
there is a report that 
mutant beclin-1 is 
located in the nucle-
us [35]. Therefore, 
we suspect that the 
nuclear expression of 
beclin-1 is not related 
to autophagy regula-
tion. Previous investi-
gators have studied 
the correlation bet- 
ween beclin-1 expres-
sion and prognosis; 
some tumors with 
beclin-1 expression 
were associated with 
poor prognosis, while 
others showed a 
favorable prognosis 
[18, 27, 31, 36]. Me- 
anwhile, both loss of 
and overexpression 
of beclin-1 has been 
associated with poor 
prognosis in colon ca- 
ncer patients [37]. Th- 
us, we cannot deter-
mine whether the ex- 
pression of beclin-1 
is associated with pr- 
ognosis in cancer pa- 
tients unless further 
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